share_log

Femasys | 8-K/A: Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update

Femasys | 8-K/A: Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update

Femasys | 8-K/A：Femasys公布截至2024年9月30日的季度财务业绩，并提供公司最新情况
美股SEC公告 ·  2024/11/13 06:05

Moomoo AI 已提取核心信息

Femasys reported strong Q3 2024 results with sales increasing 127.1% YoY to $554,908, primarily driven by initial FemaSeed and FemVue sales. The company achieved significant commercial milestones, including partnerships with Boston IVF and strategic distribution agreements in Spain expected to generate over $1.3 million in the next year.Research and development expenses rose 11.1% YoY to $2.3 million, while net loss widened to $5.4 million ($0.24 per share) compared to $4.0 million ($0.26 per share) in Q3 2023. The company maintained $7.6 million in cash and cash equivalents as of September 30, 2024, expected to fund operations into July 2025.Notable achievements include receiving FDA 510(k) clearance for FemChec, CE Mark certification for FemVue MINI, and a new U.S. patent for FemBloc. The company successfully launched FemaSeed commercialization in both U.S. and European markets, with additional sales expected in Q4 2024.
Femasys reported strong Q3 2024 results with sales increasing 127.1% YoY to $554,908, primarily driven by initial FemaSeed and FemVue sales. The company achieved significant commercial milestones, including partnerships with Boston IVF and strategic distribution agreements in Spain expected to generate over $1.3 million in the next year.Research and development expenses rose 11.1% YoY to $2.3 million, while net loss widened to $5.4 million ($0.24 per share) compared to $4.0 million ($0.26 per share) in Q3 2023. The company maintained $7.6 million in cash and cash equivalents as of September 30, 2024, expected to fund operations into July 2025.Notable achievements include receiving FDA 510(k) clearance for FemChec, CE Mark certification for FemVue MINI, and a new U.S. patent for FemBloc. The company successfully launched FemaSeed commercialization in both U.S. and European markets, with additional sales expected in Q4 2024.
Femasys报告了2024年第三季度强劲的业绩，销售额同比增长127.1%至554,908美元，主要得益于FemaSeed和FemVue的初步销售。公司达成了重要的商业里程碑，包括与Boston IVF的合作以及在西班牙的战略分销协议，预计明年将产生超过130万的收入。研发费用同比增加11.1%，达到230万，而净亏损扩大至540万（每股0.24美元），相比之下2023年第三季度为400万（每股0.26美元）。截至2024年9月30日，公司保持760万的现金及现金等价物，预计将支持其运营至2025年7月。值得一提的成就包括获得FDA 510(k)认证的FemChec、FemVue MINI的CE标记认证以及FemBloc的新美国专利。公司在美国和欧洲市场成功推出了FemaSeed商业化，预计在2024年第四季度会有额外的销售。
Femasys报告了2024年第三季度强劲的业绩，销售额同比增长127.1%至554,908美元，主要得益于FemaSeed和FemVue的初步销售。公司达成了重要的商业里程碑，包括与Boston IVF的合作以及在西班牙的战略分销协议，预计明年将产生超过130万的收入。研发费用同比增加11.1%，达到230万，而净亏损扩大至540万（每股0.24美元），相比之下2023年第三季度为400万（每股0.26美元）。截至2024年9月30日，公司保持760万的现金及现金等价物，预计将支持其运营至2025年7月。值得一提的成就包括获得FDA 510(k)认证的FemChec、FemVue MINI的CE标记认证以及FemBloc的新美国专利。公司在美国和欧洲市场成功推出了FemaSeed商业化，预计在2024年第四季度会有额外的销售。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Femasys
    FEMY
    -- 1.5900
    Predictive Oncology
    POAI
    -- 1.6200
    West Pharmaceutical Services
    WST
    -- 214.730
    NexGel
    NXGL
    -- 3.530
    BioNano Genomics
    BNGO
    -- 5.7600
    解锁完整榜单
    热门讨论
    特朗普2.0时代开启，全球市场会如何演变？
    🎙️讨论： 1. 关税政策将如何影响美股、黄金、比特币等核心资产的走势？ 2. 在此背景下，有哪些投资机会值得关注？你会如何布局？ 展开
    MicroStrategy 2024年第四季度业绩电话会
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。